# Somagenetix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/somagenetix

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.somagenetix.com/
- Total disclosed funding: $12M
- Latest round: Series A (Oct 8, 2024)
- Investors on record: 4

## About

Based in Zurich, Switzerland, Somagenetix operates as a biotechnology company that develops gene therapies for phagocyte-related disorders, targeting immunodeficiency, neurodegeneration, and cancer through enhanced phagocyte treatments. In October 2024, Somagenetix raised CHF 10 million in series A funding, led by Vi Partners, with the participation of Schroders Capital, Zürcher Kantonalbank and Verve Ventures.

Somagenetix is a developing biotech startup working to advance gene therapy for phagocyte abnormalities, with the goal of providing effective, one-time therapies for genetic disorders. The company's important approach employs lentivirus-transduced stem cells to ensure safety, specificity, and long-term efficacy, resulting in much better patient results. The team has experience with gene therapy and is dedicated to developing treatments for hereditary and neurological disorders.

The company plans to use the October 2024 funding to advance its leading gene therapy-candidate, SGX-001, into a clinical trial for treating p47 Chronic Granulomatous Disease.

## Funding rounds

- Series A, Oct 8, 2024, $12M — Schroders Capital, Zürcher Kantonalbank, Vi Partners, Verve Ventures

## Investors

- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series A
- Zürcher Kantonalbank — Series A
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series A